The objective of the proposal is to establish stable cell lines that reliably reflect human cardiomyocyte properties by the development of models derived from human embryonic stem cells.
The aim is to deliver reliable in vitro models that could be used by the pharmaceutical industry to replace experimental animals in:
- investigations on pharmacological toxicity and safety of compounds in the drug discovery and development processes, and
- the testing of toxic effects of chemicals according to the new system of the Community on the Registration, Evaluation and Authorisation of Chemicals (REACH).
In the pharmaceutical industry reliable in vitro cell models would contribute to replace current techniques with animal experimentation in the selection and optimisation of lead compounds and in documentation of a selected drug candidate before it enters clinical phases. In the toxicity testing of chemical substances replacement of animal testing methods can be attained as well.